Product Launch Tracker: eHCPs thrilled about approval of first oral treatment for postpartum depression

01.09.2023 | Tracker

Product Launch Tracker: eHCPs thrilled about approval of first oral treatment for postpartum depression

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout August 2023 we tracked the global conversations of 1,889 eHCPs who posted 2,896 English-language X (formerly Twitter) posts about the launches and approvals of new products.

In August, slightly more eHCPs discussed treatment approvals compared to the previous month. eHCPs offered their thoughts on the approval of Abrysvo, an RSV vaccine which is administered to pregnant women to protect infants from birth, as well as Zurzuvae, a postpartum depression treatment.

On 04 August, the FDA granted full approval to Zurzuvae (zuranolone), the first oral treatment for postpartum depression by Sage Therapeutics. Up until now, the only way to receive treatment for postpartum depression was via an IV injection administered in healthcare facilities. eHCPs were delighted with the approval, with a few mentioning the impressive and speedy results of the novel treatment. eHCPs referred to it as a “potential milestone” and were excited for the expansion of their options.

On 10 August, the FDA announced the approval of Talvey (talquetamab) by Janssen, a first in class specific therapy for the treatment of patients with heavily pretreated multiple myeloma. eHCPs shared the news mentioning that they are excited for having another safe and effective treatment available. Certain eHCPs were particularly excited about the approval describing the treatment as “great for patients”.

On 21 August, the FDA granted approval to Abrysvo, a single dose vaccine for the prevention of Respiratory Syncytial Virus (RSV). It is the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused RSV in infants from birth through 6 months of age. eHCPs shared the approval with their peers commenting on the fact that it protects infants from birth. A number of eHCPs were thrilled about the approval calling it ‘great news’ for preventing infants suffering.

The three most shared links from eHCPs discussing product launches in August were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal or review all previous editions of the Product Launch Tracker.

 

Methodology

  • Using CREATION Pinpoint® the English-language X conversations of eHCPs globally discussing new pharmaceutical product launches and drug approvals between 1 August and 31 August 2023 were analysed in order to discover which new product launches eHCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by eHCPs in their X conversations.
  • Between 1 August and 31 August 2023, there were 2,896 eHCP mentions of new pharmaceutical product launches and drug approvals from 1,889 unique eHCP authors from around the world. 

 

Share this article

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next


A CREATION Press Release

07.06.2013 | Press Release

Arrhythmia most talked about subject by doctors in new social media study on heart disease

Arrhythmia most talked about subject by doctors in new social media study on heart disease

Groundbreaking’ TAVR data set to change practice, say HCPs at #ACC19

03.04.2019 | Article

‘Groundbreaking’ TAVR data set to change practice, say HCPs at #ACC19

‘Groundbreaking’ TAVR data set to change practice, say HCPs at #ACC19

By Laura Marsh

View all articles >